Multiple sclerosis (MS) is the most common chronic, inflammatory, autoimmune disease of the central nervous system (CNS) maintained by the secretion of a large number of cytokines [1]. The signal transducer and activator of transcription (STAT) family has an essential role in transmitting many of the cytokine-mediated signals and failure in the signaling process contributes to the etiopathogenesis of MS.
METHODS:
This study aimed to assess STAT1, STAT2 and STAT3 gene expression in the blood of 50 relapsing-remitting MS (RR-MS) patients and 50 healthy controls by TaqMan Quantitative Real-Time PCR.
RESULTS:
The results showed that STAT1 gene expression was significantly up-regulated ( 0.023), whereas STAT2 gene expression was significantly down-regulated ( 0.0001) in MS patients compared to controls. On the other hand, there was no significant difference between MS patients and controls for STAT3 gene expression ( 0.837). In addition, there was no significant correlation between the expression of STAT1, STAT2, STAT3 genes and clinical findings, such as the level of physical disability in MS patients (according to the Kurtzke Expanded Disability Status Scale (EDSS) criterion) and disease duration.
CONCLUSION:
A significant positive correlation was demonstrated between STAT1 and STAT2 and also between STAT1 and STAT3. This study shows for the first time that a comparison of the relative quantitative expression of three different STAT genes in the blood cells of MS patients compared to controls revealed marked differences in the expression of the STAT family genes that might reflect their different roles in the pathogenesis of MS. These transcripts might be useful biomarkers for evaluating the efficacy of IFN treatment of the MS patients.
RahimiM. et al., Soluble Receptor for Advanced Glycation End Products (sRAGE) is Up-Regulated in Multiple Sclerosis Patients Treated with Interferon beta-1a, Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology46 (2018), 561–567.
2.
EftekharianM.M. et al., Frequency of viral infections and environmental factors in multiple sclerosis, Human Antibodies24 (2016), 17–23.
3.
WeinerH.L., Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease, Archives of Neurology61 (2004), 1613–1615.
4.
SatoN. and MiyajimaA., Multimeric cytokine receptors: common versus specific functions, Current Opinion in Cell Biology6 (1994), 174–179.
5.
TaheriM. et al., Determination of cytokine levels in multiple sclerosis patients and their relevance with patients’ response to Cinnovex, Cytokine96 (2017), 138–143.
6.
BenvenisteE.N.LiuY.McFarlandB.C. and QinH., Involvement of the janus kinase/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis, Journal of Interferon & Cytokine Research34 (2014), 577–588.
7.
O’SheaJ.J. and PlengeR., JAK and STAT signaling molecules in immunoregulation and immune-mediated disease, Immunity36 (2012), 542–550.
8.
BenekliM.BaerM.R.BaumannH. and WetzlerM., Signal transducer and activator of transcription proteins in leukemias, Blood101 (2003), 2940–2954.
9.
JatianiS.S.BakerS.J.SilvermanL.R. and ReddyE.P., JAK/STAT pathways in cytokine signaling and myeloproliferative disorders approaches for targeted therapies, Genes & Cancer1 (2010), 979–993.
10.
AkiraS., Functional roles of STAT family proteins: lessons from knockout mice, Stem Cells17 (1999), 138–146.
11.
AaronsonD.S. and HorvathC.M., A road map for those who don’t know JAK-STAT, Science296 (2002), 1653–1655.
12.
ConsortiumI.M.S.G., Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis, Nature Genetics45 (2013), 1353–1360.
13.
LiuY. et al., Therapeutic efficacy of suppressing the Jak/STAT pathway in multiple models of experimental autoimmune encephalomyelitis, The Journal of Immunology192 (2014), 59–72.
14.
MitchellT.J. and JohnS., Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas, Immunology114 (2005), 301–312.
15.
JeeY.KimG.TanumaN. and MatsumotoY., STAT expression and localization in the central nervous system during autoimmune encephalomyelitis in Lewis rats, Journal of Neuroimmunology114 (2001), 40–47.
16.
MaierJ.KincaidC.PagenstecherA. and CampbellI.L., Regulation of signal transducer and activator of transcription and suppressor of cytokine-signaling gene expression in the brain of mice with astrocyte-targeted production of interleukin-12 or experimental autoimmune encephalomyelitis, The American Journal of Pathology160 (2002), 271–288.
17.
WuW.X.ZuoL.DineK.E. and ShindlerK.S., Decreased signal transducers and activators of transcription (STAT) protein expression in lymphatic organs during EAE development in mice, Immunology Innovation1 (2013).
18.
SeaveyM.M. and DobrzanskiP., The many faces of Janus kinase, Biochemical Pharmacology83 (2012), 1136–1145.
19.
Fasler-KanE. et al., Human cytokines activate JAK-STAT signaling pathway in porcine ocular tissue, Xenotransplantation20 (2013), 469–480.
20.
MazdehM. et al., HLA genes as modifiers of response to IFN-beta-1a therapy in relapsing-remitting multiple sclerosis, Pharmacogenomics17 (2016), 489–498.
21.
SayadA.Ghafouri-FardS.OmraniM.D.NorooziR. and TaheriM., Myxovirus resistance protein A (MxA) polymorphism is associated with IFNbeta response in Iranian multiple sclerosis patients, Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology38 (2017), 1093–1099.
22.
PolmanC.H. et al., Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria, Annals of Neurology69 (2011), 292–302.
23.
McDonaldW.I. et al., Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis, Annals of Neurology50 (2001), 121–127.
24.
O’SheaJJ.LahesmaaR.VahediG.LaurenceA. and KannoY., Genomic views of STAT function in CD4+ T helper cell differentiation, Nature Reviews Immunology11 (2011), 239–250.
25.
AdamsonA.S.CollinsK.LaurenceA. and O’SheaJ.J., The current STATus of lymphocyte signaling: new roles for old players, Current Opinion in Immunology21 (2009), 161–166.
26.
HiraharaK. et al., Signal transduction pathways and transcriptional regulation in Th17 cell differentiation, Cytokine & Growth Factor Reviews21 (2010), 425–434.
27.
MurphyK.M. and ReinerS.L., The lineage decisions of helper T cells, Nature Reviews Immunology2 (2002), 933–944.
28.
ChenZ.LaurenceA. and O’SheaJ.J., in Seminars in immunology. (Elsevier, 2007), vol. 19, pp. 400–408.
29.
ChinY.E. et al., Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21WAF1/CIP1 mediated by STAT1, Science272 (1996), 719–722.
30.
DarnellJ.E.KerrI.M. and StarkG.R., Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins, Science264 (1994), 1415–1421.
31.
DarnellJ.E. JrKerrI.M. and StarkG.R., Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins, Science-AAAS-Weekly Paper Edition-Including Guide to Scientific Information264 (1994), 1415–1420.
32.
PlengeR., GWASs and the age of human as the model organism for autoimmune genetic research, Genome Biology11 (2010), 1.
33.
StoneL.A. et al., Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure, Neurology49 (1997), 862–869.
34.
ArababadiM.K. et al., Cytokine patterns after therapy with Avonex(R), Rebif(R), Betaferon(R) and CinnoVex in relapsing-remitting multiple sclerosis in Iranian patients, Biomarkers in Medicine4 (2010), 755–759.
35.
MekkyR.Y. and AbdelazizA.I., Sex hormones and HCV: an unresolved mystery, Expert Review of Gastroenterology & Hepatology7 (2013), 69–75.
36.
PanchanathanR. et al., Aim2 deficiency stimulates the expression of IFN-inducible Ifi202, a lupus susceptibility murine gene within the Nba2 autoimmune susceptibility locus, Journal of Immunology (Baltimore, Md.: 1950)185 (2010), 7385–7393.
37.
StarrR. et al., A family of cytokine-inducible inhibitors of signalling, Nature387 (1997), 917–921.
38.
ChenW.DainesM.O. and HersheyG.K.K., Turning off signal transducer and activator of transcription (STAT): the negative regulation of STAT signaling, Journal of Allergy and Clinical Immunology114 (2004), 476–489.
39.
BocchiniC.E.KasembeliM.M.RohS.-H. and TweardyD.J., Contribution of chaperones to STAT pathway signaling, JAK-STAT3 (2014), e970459.
40.
ChangF.ZhangL.H.XuW.P.JingP. and ZhanP.Y., microRNA9 attenuates amyloid β induced synaptotoxicity by targeting calcium/calmodulin-dependent protein kinase kinase 2, Molecular Medicine Reports9 (2014), 1917–1922.
41.
LuiP.-Y.JinD.-Y. and StevensonN.J., MicroRNA: master controllers of intracellular signaling pathways, Cellular and Molecular Life Sciences72 (2015), 3531–3542.
42.
BalashovK.E.SmithD.R.KhouryS.J.HaflerD.A. and WeinerH.L., Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand, Proceedings of the National Academy of Sciences94 (1997), 599–603.
43.
BilliauA., Interferon-gamma in autoimmunity, Cytokine Growth Factor Rev7 (1996), 25–34.
44.
StarkG.R.KerrI.M.WilliamsB.R.SilvermanR.H. and SchreiberR.D., How cells respond to interferons, Annual Review of Biochemistry67 (1998), 227–264.
45.
OwensT.RennoT.TaupinV. and KrakowskiM., Inflammatory cytokines in the brain: does the CNS shape immune responses? Immunology Today15 (1994), 566–571.
46.
SegalB.M. and ShevachE.M., IL-12 unmasks latent autoimmune disease in resistant mice, The Journal of Experimental Medicine184 (1996), 771–775.
47.
SegalB.M.DwyerB.K. and ShevachE.M., An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease, The Journal of Experimental Medicine187 (1998), 537–546.
48.
MaierJ.KincaidC.PagenstecherA. and CampbellI.L., Regulation of signal transducer and activator of transcription and suppressor of cytokine-signaling gene expression in the brain of mice with astrocyte-targeted production of interleukin-12 or experimental autoimmune encephalomyelitis, The American Journal of Pathology160 (2002), 271–288.
49.
ZaheerS.WuY.BassettJ.YangB. and ZaheerA., Glia maturation factor regulation of STAT expression: a novel mechanism in experimental autoimmune encephalomyelitis, Neurochemical Research32 (2007), 2123–2131.
50.
ChenC.LiuX.WanB. and ZhangJ.Z., Regulatory properties of copolymer I in Th17 differentiation by altering STAT3 phosphorylation, The Journal of Immunology183 (2009), 246–253.
51.
EgwuaguC.E. and LarkinJ., Therapeutic targeting of STAT pathways in CNS autoimmune diseases, JAK-STAT2 (2013), e24134.
52.
JiaY. et al., Amelioration of experimental autoimmune encephalomyelitis by plumbagin through down-regulation of JAK-STAT and NF-κB signaling pathways, PLoS One6 (2011), e27006.
53.
QinH. et al., SOCS3 deficiency promotes M1 macrophage polarization and inflammation, The Journal of Immunology189 (2012), 3439–3448.
54.
ToghiM. et al., SOCS gene family expression profile in the blood of multiple sclerosis patients, Journal of the Neurological Sciences375 (2017), 481–485.
55.
HatamiM. et al., STAT5a and STAT6 gene expression levels in multiple sclerosis patients, Cytokine, 2017.
56.
HolcarM.GoropevsekA.IhanA. and AvcinT., Age-Related Differences in Percentages of Regulatory and Effector T Lymphocytes and Their Subsets in Healthy Individuals and Characteristic STAT1/STAT5 Signalling Response in Helper T Lymphocytes, Journal of Immunology Research2015 (2015), 352934.
